Company update: Global Kinetics Corporation hits significant clinical milestones on its
trajectory to revolutionise the treatment of Parkinson’s disease
Leading digital health company Global Kinetics’ ground-breaking PKGTM technology
recommended by world leading Parkinson’s experts ahead of achieving a key milestone on
the path to USA reimbursement
PORTSMOUTH, NH USA, LONDON, UK, and MELBOURNE, Australia, August 21, 2018 –
In the most recent of a series of significant clinical milestones, Global Kinetics’ innovative
wearable technology, the Personal KinetiGraph™ (PKG™), has been recommended by two
separate expert panels for routine management of Parkinson’s disease. The publications
follow on the heels of the recent announcement by the company that the American Medical
Association (AMA) has issued a set of new Category III Current Procedural Terminology®
) codes that become effective on January 1, 2019.
Until recently, Parkinson’s disease has been one of the few chronic diseases still treated via
subjective observation of symptomology. That is set to change as the PKG system is used by
clinicians around the world to provide clinically validated continuous, objective measures of
the distinguishing movement symptoms of Parkinson’s.
The two new landmark publications reflect the expert medical opinion of internationally
recognized movement disorder specialists on the utilization of the PKG measurements to
improve clinical management of Parkinson’s disease. The groups convened to examine the
ideal objective measurement tool and clinical utility of the PKG in routine assessment and care
of Parkinson’s patients.
The first publication, titled “Viewpoint and practical recommendations from a movement
disorder specialist panel on objective measurement in the clinical management of Parkinson’s
disease,” was published online in Nature journal npj Parkinson’s Disease and can be found at
https://www.nature.com/articles/s41531-018-0051-7. The second publication, titled “Role of
the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease:
recommendations from an expert panel,” was published online in Expert Review of
Key findings of these publications include:
1. The PKG is uniquely positioned to provide a continuous objective measure of patient
symptoms, including bradykinesia, which is both treatment responsive and the clearest
indicator of underlying pathological degeneration.
Bradykinesia means slowness of movement, which is related to the loss of dopamine
responsiveness in brain cells. Unlike more obvious and commonly associated
symptoms such as dyskinesia (a response to standard treatments for Parkinson’s) and
tremor, bradykinesia is often difficult for a patient to identify and for a doctor to assess.
No other clinical or research grade technology can provide passive measures of
bradykinesia – establishing the PKG as an essential objective measure of bradykinesia
in clinical decision-making.
2. The consensus findings establish the importance of the PKG’s status as a clinicallyvalidated
medical grade technology cleared by multiple regulatory bodies with CPT
codes supporting clinical use.
The PKG system is cleared to market for clinical use in 17 countries, including FDA
clearance for the US and CE marking for Europe.
3. Early clinical evidence and expert opinion suggest a role for the PKG in influencing
and enhancing clinical decision-making.
In several routine clinical scenarios, use of the PKG can provide clinically meaningful
data to aid clinical decision-making.
Early clinical experience and expert opinion suggest that utilization of continuous
objective measurement technologies such as the PKG have the potential to improve
medical care in people with Parkinson’s disease.
To date, more than 30,000 patient PKG reports have been supplied to tailor therapy and
improve management for Parkinson’s patients. More than 3,000,000 recording hours have
been provided to 200 Parkinson’s specialist clinics across the world.
John Schellhorn, CEO of Global Kinetics Corporation, said, “Global Kinetics is proud to
announce this latest achievement in its commercial trajectory – and more importantly in our
mission to make a meaningful difference for all people with Parkinson’s. While there is much
interest and dialogue about wearable technologies in Parkinson’s, two international panels of
experts have recognized the value of the PKG in routine care. These publications position the
PKG as enhancing the management of Parkinson’s disease and differentiate it from other
research and investigatory tools. These studies, combined with the CPT III codes which will
become effective January 1, 2019, position the PKG as a viable tool to objectively measure
key Parkinson’s symptoms. We are excited to provide a product which will assist clinicians in
optimizing therapy for their PD patients.”
About Global Kinetics Pty Ltd.
Global Kinetics Pty Ltd. is committed to improving the lives of those with Parkinson’s disease
with advanced medical technologies. The company was formed in 2007 to commercialise its
lead product, the Personal KinetiGraph™ (PKG™), also known as the Parkinson’s
KinetiGraph™ outside the USA. Developed in conjunction with the world-renowned Florey
Institute of Neuroscience & Mental Health in Melbourne, Australia, the PKG enables the
precise monitoring, quantification, and reporting of movement symptoms in Parkinson’s. To
date, Global Kinetics has supported clinical decisions for doctors who treat patients with
Parkinson’s disease across 17 countries with more than 3,000,000 hours of clinical data from
our FDA-cleared, CE-marked PKG wearable device. Global Kinetics, a privately held
company, is headquartered in Melbourne, Australia with offices in London, UK, Minneapolis,
MN, and Portsmouth, NH, USA.
For more information, visit: www.globalkineticscorporation.com
Follow our LinkedIn updates: https://www.linkedin.com/company/globalkineticscorp
Chantal Beaudry / Amy Feldman
+1 (646) 871-8480 / +1 (212) 867-1770